Table of Contents Author Guidelines Submit a Manuscript
Journal of Nanomaterials
Volume 2016, Article ID 4591634, 8 pages
http://dx.doi.org/10.1155/2016/4591634
Review Article

Antiviral Nanodelivery Systems: Current Trends in Acyclovir Administration

1Department of Human Anatomy, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia (UPM), 43400 Serdang, Selangor, Malaysia
2Centre for Drug Delivery Research, Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, 50300 Kuala Lumpur, Malaysia
3Faculty of Pharmacy & Health Sciences, Universiti Kuala Lumpur Royal College of Medicine Perak, No. 3, Jalan Greentown, 30450 Ipoh, Perak, Malaysia

Received 4 April 2016; Revised 19 July 2016; Accepted 25 July 2016

Academic Editor: Changyang Gong

Copyright © 2016 Haniza Hassan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. B. Elion, “The biochemistry and mechanism of action of acyclovir,” Journal of Antimicrobial Chemotherapy, vol. 12, pp. 9–17, 1983. View at Google Scholar · View at Scopus
  2. G. B. Elion, “Acyclovir: discovery, mechanism of action, and selectivity,” Journal of Medical Virology, vol. 1, supplement 1, pp. 2–6, 1993. View at Google Scholar · View at Scopus
  3. J. Piret and G. Boivin, “Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management,” Antimicrobial Agents and Chemotherapy, vol. 55, no. 2, pp. 459–472, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. J. P. Smith, S. Weller, B. Johnson, J. Nicotera, J. M. Luther, and D. W. Haas, “Pharmacokinetics of acyclovir and its metabolites in cerebrospinal fluid and systemic circulation after administration of high-dose valacyclovir in subjects with normal and impaired renal function,” Antimicrobial Agents and Chemotherapy, vol. 54, no. 3, pp. 1146–1151, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. R. J. Whitley, M. R. Blum, N. Barton, and P. De Miranda, “Pharmacokinetics of acyclovir in humans following intravenous administration. A model for the development of parenteral antivirals,” The American Journal of Medicine, vol. 73, no. 1, pp. 165–171, 1982. View at Publisher · View at Google Scholar · View at Scopus
  6. J.-M. Poirier, N. Radembino, and P. Jaillon, “Determination of acyclovir in plasma by solid-phase extraction and column liquid chromatography,” Therapeutic Drug Monitoring, vol. 21, no. 1, pp. 129–133, 1999. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Kubbinga, M. A. Nguyen, P. Staubach, S. Teerenstra, and P. Langguth, “The influence of chitosan on the oral bioavailability of acyclovir—a comparative bioavailability study in humans,” Pharmaceutical Research, vol. 32, no. 7, pp. 2241–2249, 2015. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Wald, J. Benedetti, G. Davis, M. Remington, C. Winter, and L. Corey, “A randomized, double-blind, comparative trial comparing high- and standard-dose oral acyclovir for first-episode genital herpes infections,” Antimicrobial Agents and Chemotherapy, vol. 38, no. 2, pp. 174–176, 1994. View at Publisher · View at Google Scholar · View at Scopus
  9. Y. J. Bryson, M. Dillon, M. Lovett et al., “Treatment of first episodes of genital herpes simplex virus infection with oral acyclovir. A randomized double-blind controlled trial in normal subjects,” The New England Journal of Medicine, vol. 308, no. 16, pp. 916–921, 1983. View at Publisher · View at Google Scholar · View at Scopus
  10. G. W. Raborn, W. T. McGaw, M. Grace, L. D. Tyrrell, and S. M. Samuels, “Oral acyclovir and herpes labialis: a randomized, double-blind, placebo-controlled study,” The Journal of the American Dental Association, vol. 115, no. 1, pp. 38–42, 1987. View at Publisher · View at Google Scholar · View at Scopus
  11. H. Shirazi, M. Daneshpour, S. Kashanian, and K. Omidfar, “Synthesis, characterization and in vitro biocompatibility study of Au/TMC/Fe3O4 nanocomposites as a promising, nontoxic system for biomedical applications,” Beilstein Journal of Nanotechnology, vol. 6, no. 1, pp. 1677–1689, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. M. B. Chaudhari, P. P. Desai, P. A. Patel, and V. B. Patravale, “Solid lipid nanoparticles of amphotericin B (AmbiOnp): in vitro and in vivo assessment towards safe and effective oral treatment module,” Drug Delivery and Translational Research, vol. 6, no. 4, pp. 354–364, 2016. View at Publisher · View at Google Scholar
  13. Y. Oh, N. Lee, H. W. Kang, and J. Oh, “In vitro study on apoptotic cell death by effective magnetic hyperthermia with chitosan-coated MnFe2O4,” Nanotechnology, vol. 27, no. 11, article 115101, 2016. View at Publisher · View at Google Scholar · View at Scopus
  14. B. Sapra, P. Thatai, S. Bhandari, J. Sood, M. Jindal, and A. Tiwary, “A critical appraisal of microemulsions for drug delivery—part I,” Therapeutic Delivery, vol. 4, no. 12, pp. 1547–1564, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. D. Patel and K. K. Sawant, “Oral bioavailability enhancement of acyclovir by self-microemulsifying drug delivery systems (SMEDDS),” Drug Development and Industrial Pharmacy, vol. 33, no. 12, pp. 1318–1326, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. P. K. Ghosh, R. J. Majithiya, M. L. Umrethia, and R. S. R. Murthy, “Design and development of microemulsion drug delivery system of acyclovir for improvement of oral bioavailability,” AAPS PharmSciTech, vol. 7, no. 3, p. 77, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Gandhi, S. Jana, and K. K. Sen, “In-vitro release of acyclovir loaded Eudragit RLPO® nanoparticles for sustained drug delivery,” International Journal of Biological Macromolecules, vol. 67, pp. 478–482, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Paul, A. Kumar, P. Yedurkar, and K. Sawant, “Design and development of multiple emulsion for enhancement of oral bioavailability of acyclovir,” Drug Development and Industrial Pharmacy, vol. 39, no. 11, pp. 1809–1817, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. B. B. Ghera, F. Perret, Y. Chevalier, and H. Parrot-Lopez, “Novel nanoparticles made from amphiphilic perfluoroalkyl α-cyclodextrin derivatives: preparation, characterization and application to the transport of acyclovir,” International Journal of Pharmaceutics, vol. 375, no. 1-2, pp. 155–162, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. U. Sili, A. Kaya, A. Mert et al., “Herpes simplex virus encephalitis: clinical manifestations, diagnosis and outcome in 106 adult patients,” Journal of Clinical Virology, vol. 60, no. 2, pp. 112–118, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. X. Zhang, Y. Li, H. Zhou et al., “Plasma metabolic profiling analysis of nephrotoxicity induced by acyclovir using metabonomics coupled with multivariate data analysis,” Journal of Pharmaceutical and Biomedical Analysis C, vol. 97, pp. 151–156, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Seedat and G. Winnett, “Acyclovir-induced acute renal failure and the importance of an expanding waist line,” BMJ Case Reports, 2012. View at Publisher · View at Google Scholar
  23. H. Lu, Y.-J. Han, J.-D. Xu, W.-M. Xing, and J. Chen, “Proteomic characterization of acyclovir-induced nephrotoxicity in a mouse model,” PLoS ONE, vol. 9, no. 7, Article ID e103185, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. R. Fleischer and M. Johnson, “Acyclovir nephrotoxicity: a case report highlighting the importance of prevention, detection, and treatment of acyclovir-induced nephropathy,” Case Reports in Medicine, vol. 2010, Article ID 602783, 3 pages, 2010. View at Publisher · View at Google Scholar
  25. A. O. Kamel, G. A. S. Awad, A. S. Geneidi, and N. D. Mortada, “Preparation of intravenous stealthy acyclovir nanoparticles with increased mean residence time,” AAPS PharmSciTech, vol. 10, no. 4, pp. 1427–1436, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Gupta, A. Agarwal, N. K. Gupta, G. Saraogi, H. Agrawal, and G. P. Agrawal, “Galactose decorated PLGA nanoparticles for hepatic delivery of acyclovir,” Drug Development and Industrial Pharmacy, vol. 39, no. 12, pp. 1866–1873, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. Y. Jin, L. Tong, P. Ai, M. Li, and X. Hou, “Self-assembled drug delivery systems: 1. Properties and in vitro/in vivo behavior of acyclovir self-assembled nanoparticles (SAN),” International Journal of Pharmaceutics, vol. 309, no. 1-2, pp. 199–207, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Rao, M. J. Abzug, P. Carosone-Link et al., “Intravenous acyclovir and renal dysfunction in children: A Matched Case Control Study,” The Journal of Pediatrics, vol. 166, no. 6, pp. 1462.e4–1468.e4, 2015. View at Publisher · View at Google Scholar · View at Scopus
  29. A. B. Nair, “Quantification of uptake and clearance of acyclovir in skin layers,” Antiviral Therapy, vol. 21, no. 1, pp. 17–25, 2015. View at Publisher · View at Google Scholar
  30. S. Ghosh, V. Jhanji, E. Lamoureux, H. R. Taylor, and R. B. Vajpayee, “Acyclovir therapy in prevention of recurrent herpetic keratitis following penetrating keratoplasty,” American Journal of Ophthalmology, vol. 145, no. 2, pp. 198–202, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. G. E. Parry, P. Dunn, V. P. Shah, and L. K. Pershing, “Acyclovir bioavailability in human skin,” The Journal of Investigative Dermatology, vol. 98, no. 6, pp. 856–863, 1992. View at Publisher · View at Google Scholar · View at Scopus
  32. S. A. Qureshi, M. Jiang, K. K. Midha, and J. P. Skelly, “In vitro evaluation of percutaneous absorption of an acyclovir product using intact and tape-stripped human skin,” Journal of Pharmacy & Pharmaceutical Sciences, vol. 1, no. 3, pp. 102–107, 1998. View at Google Scholar · View at Scopus
  33. J. C. Schwarz, V. Klang, S. Karall, D. Mahrhauser, G. P. Resch, and C. Valenta, “Optimisation of multiple W/O/W nanoemulsions for dermal delivery of aciclovir,” International Journal of Pharmaceutics, vol. 435, no. 1, pp. 69–75, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. G. Shishu, S. Rajan, and Kamalpreet, “Development of novel microemulsion-based topical formulations of acyclovir for the treatment of cutaneous herpetic infections,” AAPS PharmSciTech, vol. 10, no. 2, pp. 559–565, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. R. Cortesi, L. Ravani, E. Menegatti, M. Drechsler, and E. Esposito, “Colloidal dispersions for the delivery of acyclovir: A Comparative Study,” Indian Journal of Pharmaceutical Sciences, vol. 73, no. 6, pp. 687–693, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. D. Ramyadevi and P. Sandhya, “Dual sustained release delivery system for multiple route therapy of an antiviral drug,” Drug Delivery, vol. 21, no. 4, pp. 276–292, 2014. View at Publisher · View at Google Scholar · View at Scopus
  37. E. Miserocchi, G. Fogliato, I. Bianchi, F. Bandello, and G. Modorati, “Clinical features of ocular herpetic infection in an Italian referral center,” Cornea, vol. 33, no. 6, pp. 565–570, 2014. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Burrel, D. Boutolleau, G. Azar et al., “Phenotypic and genotypic characterization of acyclovir-resistant corneal HSV-1 isolates from immunocompetent patients with recurrent herpetic keratitis,” Journal of Clinical Virology, vol. 58, no. 1, pp. 321–324, 2013. View at Publisher · View at Google Scholar · View at Scopus
  39. O. Alekseev, A. H. Tran, and J. Azizkhan-Clifford, “Ex vivo organotypic corneal model of acute epithelial herpes simplex virus type I infection,” Journal of Visualized Experiments, no. 69, Article ID e3631, 2012. View at Google Scholar · View at Scopus
  40. C. Bucolo, F. Drago, and S. Salomone, “Ocular drug delivery: a clue from nanotechnology,” Frontiers in Pharmacology, vol. 3, article 188, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. D. D. Garcia, Q. Farjo, D. C. Musch, and A. Sugar, “Effect of prophylactic oral acyclovir after penetrating keratoplasty for herpes simplex keratitis,” Cornea, vol. 26, no. 8, pp. 930–934, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Fresta, A. M. Panico, C. Bucolo, C. Giannavola, and G. Puglisi, “Characterization and in-vivo ocular absorption of liposome-encapsulated acyclovir,” The Journal of Pharmacy and Pharmacology, vol. 51, no. 5, pp. 565–576, 1999. View at Publisher · View at Google Scholar · View at Scopus
  43. S. L. Law, K. J. Huang, and C. H. Chiang, “Acyclovir-containing liposomes for potential ocular delivery: corneal penetration and absorption,” Journal of Controlled Release, vol. 63, no. 1-2, pp. 135–140, 2000. View at Publisher · View at Google Scholar · View at Scopus
  44. P. Chetoni, S. Rossi, S. Burgalassi, D. Monti, S. Mariotti, and M. F. Saettone, “Comparison of liposome-encapsulated acyclovir with acyclovir ointment: ocular pharmacokinetics in rabbits,” Journal of Ocular Pharmacology and Therapeutics, vol. 20, no. 2, pp. 169–177, 2004. View at Publisher · View at Google Scholar · View at Scopus
  45. C. Giannavola, C. Bucolo, A. Maltese et al., “Influence of preparation conditions on acyclovir-loaded poly-d,l-lactic acid nanospheres and effect of PEG coating on ocular drug bioavailability,” Pharmaceutical Research, vol. 20, no. 4, pp. 584–590, 2003. View at Publisher · View at Google Scholar · View at Scopus
  46. M. Fresta, G. Fontana, C. Bucolo, G. Cavallaro, G. Giammona, and G. Puglisi, “Ocular tolerability and in vivo bioavailability of poly(ethylene glycol) (PEG)-coated polyethyl-2-cyanoacrylate nanosphere-encapsulated acyclovir,” Journal of Pharmaceutical Sciences, vol. 90, no. 3, pp. 288–297, 2001. View at Publisher · View at Google Scholar
  47. A. Leonardi, C. Bucolo, G. L. Romano et al., “Influence of different surfactants on the technological properties and in vivo ocular tolerability of lipid nanoparticles,” International Journal of Pharmaceutics, vol. 470, no. 1-2, pp. 133–140, 2014. View at Publisher · View at Google Scholar · View at Scopus
  48. R. Pignatello, C. Bucolo, and G. Puglisi, “Ocular tolerability of Eudragit RS100® and RL100® nanosuspensions as carriers for ophthalmic controlled drug delivery,” Journal of Pharmaceutical Sciences, vol. 91, no. 12, pp. 2636–2641, 2002. View at Publisher · View at Google Scholar · View at Scopus
  49. C. Bucolo, A. Maltese, F. Maugeri, B. Busà, G. Puglisi, and R. Pignatello, “Eudragit RL100 nanoparticle system for the ophthalmic delivery of cloricromene,” The Journal of Pharmacy and Pharmacology, vol. 56, no. 7, pp. 841–846, 2004. View at Publisher · View at Google Scholar · View at Scopus
  50. S. Misra, K. Chopra, V. R. Sinha, and B. Medhi, “Galantamine-loaded solid–lipid nanoparticles for enhanced brain delivery: preparation, characterization, in vitro and in vivo evaluations,” Drug Delivery, vol. 23, no. 4, pp. 1434–1443, 2016. View at Publisher · View at Google Scholar · View at Scopus
  51. J. Albuquerque, C. C. Moura, B. Sarmento, and S. Reis, “Solid lipid nanoparticles: a potential multifunctional approach towards rheumatoid arthritis theranostics,” Molecules, vol. 20, no. 6, pp. 11103–11118, 2015. View at Publisher · View at Google Scholar · View at Scopus
  52. A. Seyfoddin and R. Al-Kassas, “Development of solid lipid nanoparticles and nanostructured lipid carriers for improving ocular delivery of acyclovir,” Drug Development and Industrial Pharmacy, vol. 39, no. 4, pp. 508–519, 2013. View at Publisher · View at Google Scholar · View at Scopus
  53. A. Seyfoddin, T. Sherwin, D. V. Patel et al., “Ex vivo and in vivo evaluation of chitosan coated nanostructured lipid carriers for ocular delivery of acyclovir,” Current Drug Delivery, In press